MDWD vs RCEL
MDWD: MediWound develops enzymatic biotherapies that debride wounds and burns by removing dead tissue, targeting faster healing with biological precision. RCEL: A therapeutic wound care company commercializing RECELL, an autologous cell harvesting device that creates patient-derived skin cell suspension for treating burns and traumatic injuries, now expanding into a multi-product acute wound care platform.
Side-by-side fundamentals
| Metric | MDWD | RCEL | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $14.45 | $4.75 | |
| Market cap as of 2026-08-01 | $181M | $138M | |
| PEG as of 2026-08-01 | -0.76 | n/a | |
| Net margin as of 2026-08-01 | -180.3% | -62.7% | RCEL higher |
| Gross margin as of 2026-08-01 | +19.6% | +82.1% | RCEL higher |
| Operating margin as of 2026-08-01 | -193.5% | -54.6% | RCEL higher |
| ROE as of 2026-08-01 | -67.2% | -337.9% | MDWD higher |
| ROA as of 2026-08-01 | -31.9% | -78.9% | MDWD higher |
| Debt / equity as of 2026-08-01 | 0.20 | 9.39 | MDWD lower |
| Revenue growth (YoY) as of 2026-08-01 | -24.6% | +1.0% | RCEL higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +27.7% | |
| Beta as of 2026-08-01 | 0.14 | 1.85 | |
| 1-year return as of 2026-07-27 close | -28.9% | -17.7% | RCEL higher |
Fundamentals: market data, as of 2026-08-01. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.